Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Consolidated Net Income (2016 - 2025)

Lipocine's Consolidated Net Income history spans 13 years, with the latest figure at -$3.2 million for Q3 2025.

  • For Q3 2025, Consolidated Net Income fell 43.63% year-over-year to -$3.2 million; the TTM value through Sep 2025 reached -$5.5 million, down 34.99%, while the annual FY2024 figure was $8352.0, 100.05% up from the prior year.
  • Consolidated Net Income reached -$3.2 million in Q3 2025 per LPCN's latest filing, down from -$2.2 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $12.6 million in Q4 2021 to a low of -$6.8 million in Q2 2021.
  • Average Consolidated Net Income over 5 years is -$1.8 million, with a median of -$2.6 million recorded in 2022.
  • Peak YoY movement for Consolidated Net Income: soared 379.83% in 2021, then tumbled 176.07% in 2023.
  • A 5-year view of Consolidated Net Income shows it stood at $12.6 million in 2021, then tumbled by 117.66% to -$2.2 million in 2022, then dropped by 2.35% to -$2.3 million in 2023, then soared by 178.09% to $1.8 million in 2024, then plummeted by 278.82% to -$3.2 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Consolidated Net Income are -$3.2 million (Q3 2025), -$2.2 million (Q2 2025), and -$1.9 million (Q1 2025).